Varma Mutual Pension Insurance Co Has $11.96 Million Position in IQVIA Holdings Inc. $IQV

Varma Mutual Pension Insurance Co reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.9% during the 4th quarter, HoldingsChannel reports. The firm owned 53,050 shares of the medical research company’s stock after selling 5,200 shares during the quarter. Varma Mutual Pension Insurance Co’s holdings in IQVIA were worth $11,958,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. bought a new position in IQVIA in the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its position in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. increased its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Measured Wealth Private Client Group LLC bought a new position in IQVIA in the 3rd quarter worth approximately $30,000. Finally, Activest Wealth Management increased its position in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $160.64 on Tuesday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $27.26 billion, a P/E ratio of 20.44, a P/E/G ratio of 1.57 and a beta of 1.18. The business’s fifty day moving average is $169.36 and its two-hundred day moving average is $201.53. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on IQV shares. Morgan Stanley set a $240.00 price target on IQVIA in a research report on Wednesday, February 11th. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Citigroup lowered their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $226.63.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.